The Influence of Diabetes Mellitus Duration and Type of Therapy on Cognitive Decline

Khairullin I., Abakumova A., Esin R., Esin O. Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

Abstract

© 2016, Springer Science+Business Media New York. We studied 120 patients with compensated diabetes mellitus type 2 (DM-2). The inclusion criterion was the absence of memory loss complaints from the patient and/or his/her relatives. The exclusion criteria were diabetes decompensation, myocardial infarction and/or stroke in anamnesis, glomerular filtration rate below 60 ml/min, the presence of proliferative retinopathy, and/or other endocrine diseases. To diagnose the cognitive decline (CD) we used Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA test), Trail Making Test (parts A and B). 77.5 % patients with type 2 diabetes out of 120 had moderate CD; 5 % had a significant CD (dementia). The control group consisted of 50 patients with arterial hypertension, which was comparable with the DM-2 group. In assessing the correlations, we found that the CD in DM-2 group is independent of disease duration and the type of diabetic therapy. We discovered a positive correlation between the age of patients and the speed of cognitive decline. Comparison of patients in DM-2 group with the control group showed that results in patients with hypertension (MMSE, MoCA test) were significantly higher (p < 0.01), and the test time of TMT part A and part B was significantly lower (p < 0.01) than that in patients with DM-2. The authors believe that the CD in DM-2 has different pathogenic mechanisms than other complications of type 2 diabetes mellitus, in particular, the insulin resistance of brain tissue.

http://dx.doi.org/10.1007/s12668-016-0345-3

Keywords

Cognitive decline, Dementia, Diabetes mellitus type 2, Diabetic encephalopathy, Insulin resistance

References

- [1] De Jong, R. N. (1950). The nervous system complications of diabetes mellitus, with special reference to cerebrovascular changes. Journal of Nervous Mental Disease, 3(49), 181-206.
- [2] Vijayakumar, T. M. (2012). Mechanism linking cognitive impairment and diabetes mellitus. European Journal of Applied Sciences, 4(1), 01-05.
- [3] Khairullin, I., Esin, R., Pozdnyak, A. (2016). The potential for correcting cognitive decline in patients with type 2 diabetes mellitus. Neuroscience Behavioral Physics, 46(3), 360-364.
- [4] Nooyens, A., Baan, C., Spijkerman, A., Verschuren, W. (2010). Type 2 diabetes and cognitive decline in middleaged men and women: the doetinchem cohort study. Diabetes Care, 33(9), 1964-1969.
- [5] Kawamura, T., Umemura, T., Hotta, N. (2012). Cognitive impairment in diabetic patients: can diabetic control prevent cognitive decline? Journal Of Diabetes Investigation, 3(5), 413-423.

- [6] Folstein, M., Folstein, S., Mchugh, P. (1975). Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research, 12, 189–198.
- [7] MoCA Version August 18, 2010 © Z. Nasreddine MD. www.mocatest.org
- [8] Corrigan, J., & Hinkeldey, M. (1987). Relationships between parts A and B of the trail making test. Journal of Clinical Psychology, 43(4), 402–409.
- [9] Blazquez, E., Velazquez, E., Hurtado-Carneiro, V., Ruiz-Albusac J. (2014). Insulin in the brain: its pathophysiological implications for states related with central insulin resistance, type 2 Diabetes and Alzheimer's disease. Frontiers in Endocrinology, 5. doi:10.3389/fendo.2014.00161.
- [10] Vijayakumar, T. M., Sirisha, G. B. N., Begam, F., Dhanaraju, M. D. (2012). Mechanism linking cognitive impairment and diabetes mellitus. European Journal of Applied Sciences, 4(1), 1–5.
- [11] Schilling, M. A. (2016). Unraveling Alzheimer's: making sense of the relationship between diabetes and Alzheimer's disease. JAD, 51(4), 961–977. doi:10.3233/jad-150980.